



Stereoselective syntheses of chiral (3*S*,9*bS*)-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-ones

Alan R. Katritzky,* Hai-Ying He and Akhilesh K. Verma


Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, FL 32611-7200, USA

Received 18 December 2001; accepted 19 March 2002

Abstract—Chiral (3*S*,9*bS*)-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-ones **11a–11f**, **14b,14c** and **17a,b** were prepared in 78–93% yields with high stereoselectivities (d.e. >99%) by the intermolecular condensations of 2-formylbenzoic acids **10** or **13** or 2-acetylbenzoic acid **15** with chiral diamines **9a–9f** and **9h**. Compounds **9a–9f** and **9h** were readily prepared in three steps from optically active *N*-Boc- α -amino acids **5a–5d**. © 2002 Elsevier Science Ltd. All rights reserved.

1. Introduction

1,2,3,9*b*-Tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-ones **1** possess antiinflammatory, analgesic, blood pressure lowering, spasmolytic, tranquilizing, and antitussive properties,¹ and are also useful sedative and hypotensive agents.² Compounds **1** ($R^1 = \text{COCH}_2\text{NH}_2$, $R^2 = R^3 = \text{H}$, $R^4 = \text{Ar}$) exhibit analgesic activity and are effective in treating rheumatism.³ Furthermore, reductions of **1** with LiAlH_4 led to the benzodiazocines, which are appetite suppressants and central nervous system stimulants.⁴



Reported routes to 1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-ones **1** ($R^1 = \text{H}$, $R^2 = R^3 = \text{H}$, $R^4 = \text{alkyl or aryl}$) involve intermolecular condensations of 1,2-ethanediamines **2** with 2-alkanoyl-⁵ or 2-aroil-benzoic

acids **3**.^{1,5,6} 1-Acyl derivatives of **1** were prepared by the acylation of **1** ($R^1 = \text{H}$) with anhydrides^{1,6a} or acid chlorides.¹ In published examples of **1**, R^2 and R^3 groups are limited to hydrogen except for three examples (**1**: $R^1 = \text{H}$, $R^2 = R^3 = \text{CH}_3$ or Ph; $R^1 = \text{H}$, $R^2 = \text{CH}_3$, $R^3 = \text{H}$).^{6a} A less common approach to **1** involves the reactions of 1,2-ethanediamines **2** with 2-bromobenzaldehyde under carbon monoxide via a palladium-catalyzed cascade intramolecular acylpalladation–cyclization sequence.⁷ However, no stereoselective synthesis was reported, thus the final products **1** were hitherto obtained as racemic compounds or mixtures of diastereoisomers.


Following our recent stereoselective syntheses of (3*S*,9*bR*)-1*H*-imidazo[2,1-*a*]isoindole-2,5(3*H*,9*bH*)-diones **4**,⁸ we now report a simple and efficient synthesis of functionalized chiral (3*S*,9*bS*)-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-ones in good to excellent yields with high stereoselectivities starting from easily available *N*-Boc- α -amino acids **5**.

2. Results and discussion

2.1. Preparation of chiral diamines **9a–9f** from *N*-Boc- α -amino acids **5a–5d** (cf. Scheme 1)

The published method⁹ readily provided *N*-Boc- α -amino amides **7a–7f** from the corresponding optically active *N*-Boc- α -amino acids **5a–5d** ($R^2 = \text{Me}$, *i*-Pr, *i*-Bu, or PhCH_2) and primary amines **6** ($R^1 = p\text{-CH}_3\text{C}_6\text{H}_4$, PhCH_2 , or *c*- C_6H_{11}). We previously used excess HCl/

* Corresponding author. Tel.: +1 352 392 0554; fax: +1 352 392 9199; e-mail: katritzky@chem.ufl.edu



Scheme 1. For designation of R^1 and R^2 in series **a–f**, see Table 1. *Reagents and conditions:* (i) $\text{ClCOOBu}-i$, *N*-methylmorpholine; (ii) CF_3COOH ; (iii) aq. NaOH ; (iv) $\text{LiAlH}_4/\text{THF}$; (v) *p*- TsoH , PhH , Dean–Stark.

EtOAc (ca. 1 M) to remove the *N*-Boc protection group (usually needing 12–24 h until the disappearance of **7**),⁸ but we now find that use of CF_3COOH (8 equiv.) in dry CH_2Cl_2 is a more efficient method to remove the Boc group (needing only 2–5 h) to give α -amino amides **8a–8f** (88–96%).

Crombie and Hooper reduced 2-amino-*N*-phenylpropanamide with LiAlH_4 to 2-aminopropylaniline without reporting a detailed procedure.¹⁰ Reduction of **8b** ($R^1 = p\text{-CH}_3\text{C}_6\text{H}_4$, $R^2 = i\text{-Bu}$) with 3 equiv. of LiAlH_4 in refluxing THF for 1 day gave a 1:1 mixture of **8b** and **9b**. When 6 equiv. of LiAlH_4 was used in refluxing THF for 2 days, chiral diamines **9a–9f** were obtained in more than 90% yields. Intermediates **7**, **8** and **9** were used as crude products without further purification for the subsequent steps.

2.2. Syntheses and stereoselectivities of (3*S*,9*bS*)-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-ones **11a–11f**

Optically active (3*S*,9*bS*)-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-ones **11a–11f** were prepared as

Table 1. Isolated yields of **11a–11f** with d.e. values

No.	R^1	R^2	Yield 11 ^a (d.e. ^b %)
a	<i>p</i> - $\text{CH}_3\text{C}_6\text{H}_4$ -	CH_3	78 (>99)
b	<i>p</i> - $\text{CH}_3\text{C}_6\text{H}_4$ -	<i>i</i> -Bu	90 (>99)
c	<i>p</i> - $\text{CH}_3\text{C}_6\text{H}_4$ -	PhCH_2 -	88 (>99)
d	<i>p</i> - $\text{CH}_3\text{C}_6\text{H}_4$ -	<i>i</i> -Pr	93 (>99)
e	<i>c</i> - C_6H_{11}	<i>i</i> -Pr	78 (>99)
f	PhCH_2 -	<i>i</i> -Pr	89 (>99)
g	Ph	H	74 ^c

^a Isolated yield based on the chiral diamine **9a–9f**.

^b Determined by the ^1H NMR spectrum.

^c Compound **11g** was obtained from *N*¹-phenyl-1,2-ethanediamine **9g** and **10** using azeotropic distillation in toluene for 28 h.

single enantiomers in 78–93% yields by the reactions of 2-formylbenzoic acid **10** with 1 equiv. of the chiral diamines **9a–9f** and catalytic *p*-toluenesulfonic acid (0.1 equiv.) in refluxing benzene for 12 h with a Dean–Stark apparatus to remove the water formed (Scheme 1). The isolated yields and the d.e. values (determined by the ^1H NMR spectra) of **11a–11f** are summarized in Table 1. Structures **11a–11f** are clearly supported by their ^1H , ^{13}C , NOESY NMR spectra and microanalyses. It is noteworthy that the same conditions for the reaction of **10** and *N*¹-phenyl-1,2-ethanediamine **9g** gave the desired **11g** in low yield (<10%); while completing the reaction under azeotropic reflux in toluene over 28 h improved the yield to 74%.

The absolute configuration of the new stereogenic center at the 9*b*-position in **11a–11f** was determined by NOESY experiments. ^1H NMR spectra show that H(9*b*) in **11a–11f** appears from 4.9 ppm to 6.1 ppm as a singlet; H(3) at 4.4–4.8 ppm as a multiplet. No distinct NOE effect was observed between H(9*b*) and H(3) in compounds **11a–11f**, when either H(9*b*) or H(3) was irradiated. This suggests that H(9*b*) and H(3) in **11a–11f** are located in a *trans*-orientation. Further irradiation of **11a** [at CH_3 (3), 1.39 ppm (d)], **11b** [at *i*- PrCH_2 -, 1.6 or 1.8 ppm (m)], **11c** [at PhCH_2 -, 2.88 or 3.09 ppm (dd)] or **11d** [at $\text{CH}(\text{CH}_3)_2$, 1.8 ppm (m)] caused a strong positive NOE effect of H(9*b*), and vice versa. The similar positive NOE effect was observed between $\text{CH}(\text{CH}_3)_2$ (3) and H(9*b*) for **11e,f**. This evidence directly demonstrates the *trans*-orientation of H(9*b*) and H(3). Therefore, enantiopure **11a–11f** were obtained as sole *trans*-isomers with the formation of three new bonds in a single step to form the tricyclic ring system.

The reaction mechanism is similar to that previously proposed.⁸ The α -amino group in **9a–9f** attacks the aldehydic carbon atom (the most electrophilic center in **10**) to generate the transient intermediate α -carbinolamine **A**, which readily eliminates a molecule of water to afford the imine intermediate with more stable *E*(*trans*)-configuration. Conformation **B** of the imine intermediate is much more stable than conformation **C** due to the larger repulsion between R^2 group and $-\text{NHR}^1$ group in **C**. Therefore, the lone electron pair of the nitrogen in the predominant conformation **B** attacks the imine from below the $\text{ArC}=\text{N}$ -coplane, followed by elimination of another water molecule, to form the *trans*-isomers **11a–11f** as the sole products. The *cis*-isomers **12a–12f** were not detected (cf. Fig. 1).

Interestingly, irradiation of **11a** [at CH_3 (3)], **11b** (at *i*- PrCH_2), **11c** (at PhCH_2) or **11d–11f** [at $\text{CH}(\text{CH}_3)_2$] also caused a distinct positive NOE effect for one of the methylene hydrogens at the 2-position, thus this hydrogen is assigned as the *anti*-proton H^a (for one example **11a**, cf. Fig. 2). *anti*- H^a always appears at higher field than *syn*- H^b and its coupling constant with H(3) (ca. 3.2 Hz) is smaller than that of *syn*- H^b with H(3) (ca. 6.9 Hz).





Figure 1.

Figure 2. Nuclear Overhauser effect for **11a**.

2.3. Syntheses of 1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones **14a,b** and **17a,b**

The reaction of 2-formyl-5,6-dimethoxybenzoic acid **13** with *N*¹-phenyl-1,2-ethanediamine **9g** gave 6,7-dimethoxy-1-phenyl-1,2,3,9b-tetrahydro-5H-imidazo[2,1-a]isoindol-5-one **14a** in 64% yield using azeotropic distillation in toluene for 28 h. Similarly, **14b** and **14c** were obtained from the reactions of **13** with **9e** and **9f** in 83 and 86% yields, respectively (Scheme 2).


Interestingly, condensation of *N*¹-phenyl-1,2-ethanediamine **9g** with 2-acetylbenzoic acid **15** produced 2-(2-anilinoethyl)-3-methylene-1-isoindolinone **16** rather than a tricyclic structure. The ¹H, ¹³C NMR spectra of **16** show the disappearance of the methyl group and the existence of two hydrogens attached to a carbon-carbon double bond. The GC-MS result [GC-MS (EI): 264 (M⁺)] together with combustion analysis data, further support the structure **16** (cf. Scheme 2). Furthermore, H^c is believed to appear at lower field (5.12 ppm, doublet); while H^d resonates at higher field (4.80 ppm, doublet), due to the positive NOE effect between H^c and H^e (7.68 ppm, doublet). The formation of **16** is probably because of competitive deprotonation at the methyl group and the deprotonation at -NPh moiety in the transient *N*-acyliminium cation.

Nevertheless, reaction of 2-acetylbenzoic acid **15** with chiral diamines **9h** and **9f** (R² ≠ H) furnished the desired enantiopure (3*S*,9*bS*)-1,2,3,9*b*-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones **17a,b** in 88 and 89% yields, respectively. The NOESY results also prove the *trans*-configurations for **17a,b** due to the positive NOE effect

between CH₃(9*b*) with CH₃(3) in **17a** and CH(CH₃)₂(3) in **17b**, respectively.

3. Conclusion

In summary, we have developed an efficient route to enantiopure (3*S*,9*bS*)-1,2,3,9*b*-tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones **11a–11f**, **14b**, **14c** and **17a** and **17b** in good to excellent yields with high stereoselectivities through intermolecular condensations of 2-formylbenzoic acids **10** or **13** or 2-acetylbenzoic acid **15** with chiral diamines **9a–9f** and **9h**, which were readily prepared in three steps from *N*-Boc- α -amino acids **5a–5d**. Thus, three new bonds are simultaneously formed in one step to generate the novel tricyclic ring system.



Scheme 2.

4. Experimental

THF was distilled from sodium/benzophenone prior to use. Melting points were determined using a Bristoline hot-stage microscope and are uncorrected. ^1H (300 MHz), ^{13}C (75 MHz) NMR spectra, and NOESY spectra were recorded on a Gemini 300 MHz NMR spectrometer in CDCl_3 (with TMS for ^1H and CDCl_3 for ^{13}C as the internal reference). Optical rotation values were measured by a Perkin–Elmer 341 polarimeter using the sodium D line. Column chromatography was performed on silica gel (200–425 mesh). All of the reactions were carried out under N_2 .

4.1. General procedures for the preparation of chiral diamines **9a–9f** and **9h** from *N*-Boc- α -amino acids **5a–5d**

Synthesis of N-Boc- α -amino amides 7a–7f: *N*-Boc- α -amino amides **7a–7f** were prepared from *N*-Boc- α -amino acids **5a–d** and primary amines **6a–6c** in more than 89% yields according to our recent paper.⁸

Removal of N-Boc protecting group: The previous conditions used to remove *N*-Boc with HCl/EtOAc were modified as follows: *N*-Boc- α -amino amide **7a–7f** (3 mmol) was treated with CF_3COOH (2.7 g, 24 mmol) in dry CH_2Cl_2 (25 mL) at room temperature until TLC showed the disappearance of **7** (usually needs 2–5 h). Usual work-up gave the α -amino amides **8a–8f** in more than 88% yields.

Reduction of 8a–8f with LiAlH₄: A mixture of the α -amino amide **8a–8f** (3 mmol) and LiAlH_4 (powder, 0.68 g, 18 mmol) in dry THF (30 mL) was heated under reflux for 2 days. The mixture was slowly quenched with water under ice-bath cooling. The precipitate formed was filtered off and washed with CH_2Cl_2 . The combined filtrate was washed with 1 M NaOH, brine and dried over anhyd. K_2CO_3 . Removal of solvents afforded chiral diamine **9a–9f**, which was directly used for the subsequent reaction. GC analyses show that the purity of **9a–9f** is more than 92%.

Compound **9h** was similarly prepared from *N*-Boc- α -amino acid **5a** ($\text{R}^2 = \text{CH}_3$) and cyclohexylamine.

4.1.1. (2*S*)-*N*¹-(4-Methylphenyl)-1,2-propanediamine **9a**. Yellowish oil; yield 96%; ^1H NMR: δ 1.20 (d, $J=7.1$ Hz, 3H), 1.20–1.80 (br s, 2H), 2.31 (s, 3H), 2.90 (dd, $J=12.1, 8.0$ Hz, 1H), 3.14–3.22 (m, 2H), 3.80–4.25 (br s, 1H), 6.62 (d, $J=8.4$ Hz, 2H), 7.05 (d, $J=8.1$ Hz, 2H); ^{13}C NMR: δ 20.1, 21.8, 45.9, 52.3, 112.8, 126.1, 129.5, 146.0.

4.1.2. (2*S*)-*N*¹-(4-Methylphenyl)-4-methyl-1,2-pentanediamine **9b**. Colorless oil; yield 93%; ^1H NMR: δ 0.91 (d, $J=6.5$ Hz, 3H), 0.95 (d, $J=6.6$ Hz, 3H), 1.28 (t, $J=6.7$ Hz, 2H), 1.20–1.40 (br s, 2H), 1.70–1.81 (m, 1H), 2.24 (s, 3H), 2.79 (dd, $J=11.8, 8.7$ Hz, 1H), 3.00–3.08 (m, 1H), 3.13–3.20 (m, 1H), 3.80–4.10 (br s, 1H), 6.56 (d, $J=8.1$ Hz, 2H), 7.00 (d, $J=8.0$ Hz, 2H); ^{13}C NMR: δ 20.3, 22.1, 23.5, 24.7, 45.7, 48.4, 51.3, 113.1, 126.5, 129.7, 146.3.

4.1.3. (2*S*)-*N*¹-(4-Methylphenyl)-3-phenyl-1,2-propanediamine **9c**. Yellowish oil; yield 94%; ^1H NMR: δ 1.02–1.40 (br s, 2H), 2.23 (s, 3H), 2.56 (dd, $J=13.3, 8.4$ Hz, 1H), 2.78–2.94 (m, 2H), 3.18–3.27 (m, 2H), 3.90–4.05 (br s, 1H), 6.53 (d, $J=8.2$ Hz, 2H), 6.97 (d, $J=8.0$ Hz, 2H), 7.18–7.32 (m, 5H); ^{13}C NMR: δ 20.3, 42.7, 50.3, 52.1, 113.0, 126.3, 126.5, 128.4, 129.1, 129.6, 138.7, 146.1.

4.1.4. (2*S*)-*N*¹-(4-Methylphenyl)-3-methyl-1,2-butanediamine **9d**. Yellowish oil; yield 91%; ^1H NMR: δ 0.94 (d, $J=6.4$ Hz, 3H), 0.96 (d, $J=6.5$ Hz, 3H), 1.17 (br s, 2H), 1.60–1.70 (m, 1H), 2.23 (s, 3H), 2.69–2.84 (m, 2H), 3.20 (dd, $J=11.4, 2.7$ Hz, 1H), 3.99 (br s, 1H), 6.56 (d, $J=8.4$ Hz, 2H), 6.98 (d, $J=8.1$ Hz, 2H); ^{13}C NMR: δ 17.8, 19.3, 20.3, 32.5, 48.5, 56.1, 113.1, 126.4, 129.7, 146.4.

4.1.5. (2*S*)-*N*¹-Cyclohexyl-3-methyl-1,2-butanediamine **9e**. Yellowish oil; yield 90%; ^1H NMR: δ 0.90 (d, $J=6.3$ Hz, 3H), 0.92 (d, $J=6.6$ Hz, 3H), 1.05–1.40 (m, 6H), 1.56–1.92 (m, 5H), 2.23 (br s, 3H), 2.32–2.48 (m, 2H), 2.56–2.62 (m, 1H), 2.77 (dd, $J=11.4, 3.3$ Hz, 1H); ^{13}C NMR: δ 17.7, 19.3, 24.8, 25.0, 26.0, 32.5, 33.2, 33.4, 50.7, 56.5, 57.0.

4.1.6. (2*S*)-*N*¹-Benzyl-3-methyl-1,2-butanediamine **9f**. Colorless oil; yield 94%; ^1H NMR: δ 0.89 (d, $J=6.9$ Hz, 3H), 0.90 (d, $J=6.6$ Hz, 3H), 1.43 (s, 3H), 1.53–1.63 (m, 1H), 2.39 (dd, $J=11.4, 9.3$ Hz, 1H), 2.58–2.69 (m, 1H), 2.72 (dd, $J=11.4, 3.3$ Hz, 1H), 3.79 (d, $J=7.5$ Hz, 2H), 7.23–7.33 (m, 5H); ^{13}C NMR: δ 17.8, 19.4, 32.3, 53.6, 54.1, 56.5, 126.8, 128.0, 128.3, 140.6.

4.1.7. (2*S*)-*N*¹-Cyclohexyl-1,2-propanediamine **9h**. Yellowish oil; yield 90%; ^1H NMR: δ 1.10 (d, $J=6.3$ Hz, 3H), 1.16–1.32 (m, 5H), 1.60–1.64 (m, 2H), 1.72–1.78 (m, 2H), 1.91–1.99 (m, 2H), 2.39–2.52 (m, 2H), 2.71 (dd, $J=11.8, 4.1$ Hz, 1H), 3.01–3.10 (m, 3H); ^{13}C NMR: δ 21.7, 24.9, 25.0, 25.9, 32.8, 33.1, 46.6, 54.3, 56.9.

4.2. General procedure for the preparation of 1,2,3,9b-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-ones **11a–11g**

A mixture of a crude diamine **9a–9f** (1.0 mmol), 2-formylbenzoic acid (10, 0.15 g, 1.0 mmol) and *p*- $\text{CH}_3\text{C}_6\text{H}_4\text{SO}_3\text{H}\cdot\text{H}_2\text{O}$ (0.02 g, 0.1 mmol) was heated under reflux in benzene (25 mL) for 12 h using a Dean–Stark apparatus. After cooling, most of the solvent was evaporated in vacuo and the residue was diluted with EtOAc. The organic phase was washed with 1 M NaOH, brine and dried over anhyd. Na_2SO_4 . After removal of solvents in vacuo, the residue was purified by column chromatography with hexanes/EtOAc (8:1 to 4:1) as an eluent to give the final product **11a–11f**.

Compound **11g** was obtained from **10** and *N*¹-phenyl-1,2-ethanediamine **9g** with 0.1 equiv. of *p*-TsOH using azeotropic distillation in toluene for 28 h.

4.2.1. (3*S*,9*bS*)-1-(4-Methylphenyl)-3-methyl-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 11a. White needles; yield 78%; mp 108–109°C; $[\alpha]_{\text{D}}^{25} = -482$ (*c* 1.68, CHCl₃); ¹H NMR: δ 1.39 (d, *J* = 6.6 Hz, 3H), 2.32 (s, 3H), 3.27 (dd, *J* = 9.2, 3.2 Hz, 1H, H^a), 4.03 (dd, *J* = 9.2, 6.9 Hz, 1H, H^b), 4.52–4.61 (m, 1H), 6.06 (s, 1H, NCHN), 6.91 (d, *J* = 8.4 Hz, 2H), 7.16 (d, *J* = 8.2 Hz, 2H), 7.49 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.70 (dd, *J* = 5.6, 3.2 Hz, 1H), 7.82 (dd, *J* = 5.5, 3.0 Hz, 1H); ¹³C NMR: δ 20.4, 20.8, 49.7, 61.0, 74.8, 115.4, 124.2, 124.3, 129.0, 129.6, 129.9, 132.4, 133.2, 144.6, 145.1, 172.4. Anal. calcd for C₁₈H₁₈N₂O: C, 77.67; H, 6.52; N, 10.06. Found: C, 77.61; H, 6.57; N, 10.11%.

4.2.2. (3*S*,9*bS*)-1-(4-Methylphenyl)-3-isobutyl-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 11b. Colorless prisms; yield 90%; mp 61–62°C; $[\alpha]_{\text{D}}^{25} = -449$ (*c* 1.78, CHCl₃); ¹H NMR: δ 0.96 (d, *J* = 6.6 Hz, 3H), 1.07 (d, *J* = 6.5 Hz, 3H), 1.33–1.39 (m, 1H), 1.56–1.63 (m, 1H), 1.80–1.85 (m, 1H), 2.31 (s, 3H), 3.27 (dd, *J* = 9.0, 2.7 Hz, 1H, H^a), 4.00 (dd, *J* = 9.3, 6.9 Hz, 1H, H^b), 4.47–4.55 (m, 1H), 6.03 (s, 1H, NCHN), 6.88 (d, *J* = 8.2 Hz, 2H), 7.15 (d, *J* = 8.0 Hz, 2H), 7.46 (dd, *J* = 5.4, 3.0 Hz, 2H), 7.71 (dd, *J* = 5.4, 3.0 Hz, 1H), 7.81 (dd, *J* = 5.4, 3.3 Hz, 1H); ¹³C NMR: δ 20.4, 21.9, 23.1, 25.3, 43.7, 52.4, 59.7, 74.5, 114.9, 124.1, 124.1, 128.5, 129.5, 129.8, 132.3, 133.2, 144.7, 145.3, 172.4. Anal. calcd for C₂₁H₂₄N₂O: C, 78.71; H, 7.55; N, 8.74. Found: C, 78.67; H, 7.83; N, 8.73%.

4.2.3. (3*S*,9*bS*)-1-(4-Methylphenyl)-3-benzyl-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 11c. White microcrystals; yield 88%; mp 128–129°C; $[\alpha]_{\text{D}}^{25} = -376$ (*c* 1.57, CHCl₃); ¹H NMR: δ 2.31 (s, 3H), 2.88 (dd, *J* = 13.9, 8.2 Hz, 1H), 3.09 (dd, *J* = 13.9, 6.2 Hz, 1H), 3.42 (dd, *J* = 9.6, 3.2 Hz, 1H, H^a), 3.87 (dd, *J* = 9.6, 6.7 Hz, 1H, H^b), 4.70–4.79 (m, 1H), 5.93 (s, 1H, NCHN), 6.83 (d, *J* = 8.5 Hz, 2H), 7.13 (d, *J* = 8.0 Hz, 2H), 7.21–7.30 (m, 5H), 7.47 (dd, *J* = 5.6, 3.1 Hz, 2H), 7.67 (dd, *J* = 5.4, 3.2 Hz, 1H), 7.81 (dd, *J* = 5.4, 3.1 Hz, 1H); ¹³C NMR: δ 20.4, 40.3, 54.9, 58.0, 75.2, 115.1, 124.1, 124.3, 126.7, 128.5, 128.8, 129.3, 129.5, 129.8, 132.4, 133.1, 137.2, 144.4, 145.4, 172.6. Anal. calcd for C₂₄H₂₂N₂O: C, 81.32; H, 6.26; N, 7.90. Found: C, 81.18; H, 6.32; N, 7.95%.

4.2.4. (3*S*,9*bS*)-1-(4-Methylphenyl)-3-isopropyl-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 11d. Colorless flakes; yield 93%; mp 55–56°C; $[\alpha]_{\text{D}}^{25} = -373$ (*c* 1.66, CHCl₃); ¹H NMR: δ 1.01 (d, *J* = 6.4 Hz, 3H), 1.03 (d, *J* = 6.4 Hz, 3H), 1.76–1.87 (m, 1H), 2.31 (s, 3H), 3.39 (dd, *J* = 9.3, 3.6 Hz, 1H, H^a), 4.02 (dd, *J* = 9.0, 7.2 Hz, 1H, H^b), 4.14 (td, *J* = 7.5, 3.6 Hz, 1H), 5.97 (s, 1H, NCHN), 6.91 (d, *J* = 8.4 Hz, 2H), 7.15 (d, *J* = 8.1 Hz, 2H), 7.45–7.48 (m, 2H), 7.68 (dd, *J* = 5.6, 3.3 Hz, 1H), 7.81 (dd, *J* = 5.6, 3.3 Hz, 1H); ¹³C NMR: δ 18.9, 19.1, 20.4, 32.5, 58.0, 59.8, 75.8, 115.5, 124.0, 124.2, 129.0, 129.4, 129.8, 132.2, 133.2, 144.6, 145.4, 172.7. Anal. calcd for C₂₀H₂₂N₂O: C, 78.40; H, 7.24; N, 9.14. Found: C, 78.01; H, 7.54; N, 9.06%.

4.2.5. (3*S*,9*bS*)-1-Cyclohexyl-3-isopropyl-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 11e. Colorless oil; yield 78%; $[\alpha]_{\text{D}}^{25} = -32.5$ (*c* 1.66, CHCl₃); ¹H NMR: δ 0.99 (d, *J* = 6.6 Hz, 3H), 1.08 (d, *J* = 6.6 Hz, 3H), 1.12–1.41 (m, 5H), 1.70–2.00 (m, 5H), 2.00–2.11 (m, 1H), 2.89–2.99 (m, 2H), 3.48 (t, *J* = 7.8 Hz, 1H), 3.78 (dt, *J* = 15.3, 15.0 Hz, 1H), 5.17 (s, 1H, NCHN), 7.44–7.54 (m, 3H), 7.80 (d, *J* = 6.9 Hz, 1H); ¹³C NMR: δ 18.6, 19.6, 24.6, 25.6, 26.2, 26.2, 32.5, 33.5, 52.9, 56.3, 59.8, 76.4, 123.4, 124.5, 129.2, 131.6, 134.2, 144.1, 173.0. Anal. calcd for C₁₉H₂₆N₂O: C, 76.47; H, 8.78; N, 9.39. Found: C, 76.30; H, 8.83; N, 9.36%.

4.2.6. (3*S*,9*bS*)-1-Benzyl-3-isopropyl-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 11f. White needles; yield 89%; mp 102–103°C; $[\alpha]_{\text{D}}^{25} = +1.3$ (*c* 1.58, CHCl₃); ¹H NMR: δ 0.94 (d, *J* = 6.9 Hz, 3H), 1.07 (d, *J* = 6.9 Hz, 3H), 1.78–1.89 (m, 1H), 2.59 (t, *J* = 9.2 Hz, 1H, H^a), 3.44–3.50 (m, 2H), 3.77 (dt, *J* = 7.8, 7.8 Hz, 1H), 4.15 (d, *J* = 12.6 Hz, 1H), 4.93 (s, 1H, NCHN), 7.26–7.31 (m, 5H), 7.39 (dd, *J* = 5.1, 3.0 Hz, 1H), 7.49–7.52 (m, 2H), 7.82 (dd, *J* = 6.6, 3.3 Hz, 1H); ¹³C NMR: δ 18.5, 19.8, 33.6, 56.5, 59.7, 60.5, 81.4, 123.3, 124.4, 127.4, 128.4, 128.7, 129.5, 131.8, 134.2, 137.5, 143.5, 173.0. Anal. calcd for C₂₀H₂₂N₂O: C, 78.40; H, 7.24; N, 9.14. Found: C, 78.20; H, 7.41; N, 9.07%.

4.2.7. 1-Phenyl-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 11g. Colorless flakes; yield 74%; mp 140–141°C; ¹H NMR: δ 3.48 (dt, *J* = 11.1, 8.4 Hz, 1H), 3.64 (td, *J* = 8.4, 2.4 Hz, 1H), 3.84 (dt, *J* = 8.3, 8.3 Hz, 1H), 4.34 (ddd, *J* = 11.1, 7.2, 2.4 Hz, 1H), 6.12 (s, 1H, NCHN), 6.90 (t, *J* = 7.5 Hz, 1H), 6.97 (d, *J* = 8.1 Hz, 2H), 7.35 (t, *J* = 8.1 Hz, 2H), 7.49–7.52 (m, 2H), 7.77 (dd, *J* = 5.1, 3.3 Hz, 1H), 7.84 (dd, *J* = 5.1, 3.3 Hz, 1H); ¹³C NMR: δ 42.1, 52.9, 75.3, 114.4, 118.9, 124.2, 124.3, 129.4, 129.6, 132.6, 132.9, 145.4, 146.5, 172.7. Anal. calcd for C₁₆H₁₄N₂O: C, 76.78; H, 5.64; N, 11.19. Found: C, 76.80; H, 5.82; N, 11.21%.

4.3. General procedure for the reaction of 2-formyl-5,6-dimethoxybenzoic acid 13 and diamines 9e–9g

Using 2-formyl-5,6-dimethoxybenzoic acid 13 instead of 2-formylbenzoic acid 10 to react with 9g, 9e or 9f, the same procedure as used for the preparation of 11g led to 14a. The same procedure as used for the preparation of 11a–11f led to 14b and 14c, respectively.

4.3.1. 1-Phenyl-6,7-dimethoxy-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 14a. Colorless flakes; yield 64%; mp 142–143°C; ¹H NMR: δ 3.39 (dt, *J* = 9.3, 9.3 Hz, 1H), 3.58 (t, *J* = 8.4 Hz, 1H), 3.82 (dt, *J* = 8.7, 8.7 Hz, 1H), 3.85 (s, 3H), 4.08 (s, 3H), 4.26–4.36 (m, 1H), 5.99 (s, 1H, NCHN), 6.86 (t, *J* = 7.2 Hz, 1H), 6.92 (d, *J* = 8.1 Hz, 2H), 7.00 (d, *J* = 8.4 Hz, 1H), 7.33 (t, *J* = 7.2 Hz, 2H), 7.39 (d, *J* = 8.4 Hz, 1H); ¹³C NMR: δ 42.1, 52.5, 56.5, 62.3, 74.2, 114.4, 116.6, 118.7, 119.1, 124.6, 129.3, 138.5, 146.5, 147.3, 153.4, 170.9. Anal. calcd for C₁₈H₁₈N₂O₃: C, 69.66; H, 5.85; N, 9.03. Found: C, 69.75; H, 6.07; N, 8.97%.

4.3.2. (3*S*,9*bS*)-1-Cyclohexyl-3-isopropyl-6,7-dimethoxy-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 14*b*. Colorless oil; yield 83%; $[\alpha]_{\text{D}}^{25} = -47.5$ (*c* 1.66, CHCl₃); ¹H NMR: δ 0.97 (d, *J* = 6.9 Hz, 3H), 1.07 (d, *J* = 6.6 Hz, 3H), 1.26–1.42 (m, 4H), 1.68–1.81 (m, 5H), 1.91–1.95 (m, 1H), 2.04–2.08 (m, 1H), 2.83–2.96 (m, 2H), 3.45 (t, *J* = 8.3 Hz, 1H), 3.75 (dt, *J* = 7.7, 7.7 Hz, 1H), 3.89 (s, 3H), 4.07 (s, 3H), 5.05 (s, 1H, NCHN), 7.06, 7.09 (AB, *J* = 8.1 Hz, 2H); ¹³C NMR: δ 18.8, 19.8, 24.4, 25.7, 26.2, 26.3, 32.7, 33.6, 52.8, 56.1, 56.6, 60.1, 62.4, 75.3, 116.1, 118.5, 126.1, 137.3, 147.6, 153.6, 171.5. Anal. calcd for C₂₁H₃₀N₂O₃: C, 70.36; H, 8.44; N, 7.81. Found: C, 70.18; H, 8.56; N, 7.79%.

4.3.3. (3*S*,9*bS*)-1-Benzyl-3-isopropyl-6,7-dimethoxy-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 14*c*. Colorless needles; yield 86%; mp 79–80°C; $[\alpha]_{\text{D}}^{25} = +4.3$ (*c* 1.66, CHCl₃); ¹H NMR: δ 0.92 (d, *J* = 6.6 Hz, 3H), 1.06 (d, *J* = 6.6 Hz, 3H), 1.72–1.83 (m, 1H), 2.52 (t, *J* = 9.3 Hz, 1H), 3.41–3.45 (m, 1H), 3.43, 4.12 (AB, *J* = 12.9 Hz, 2H), 3.74 (dt, *J* = 7.8, 7.8 Hz, 1H), 3.89 (s, 3H), 4.10 (s, 3H), 4.79 (s, 1H, NCHN), 7.03, 7.07 (AB, *J* = 8.1 Hz, 2H), 7.22–7.32 (m, 5H); ¹³C NMR: δ 18.6, 19.9, 33.6, 56.3, 56.6, 59.9, 60.3, 62.4, 80.4, 116.1, 118.3, 125.9, 127.4, 128.4, 128.7, 136.6, 137.5, 147.4, 153.4, 171.4. Anal. calcd for C₂₂H₂₆N₂O₃: C, 72.11; H, 7.15; N, 7.64. Found: C, 72.38; H, 7.08; N, 7.61%.

4.4. General procedure for the reaction of 2-acetylbenzoic acid 15 with diamines

Using 2-acetylbenzoic acid 15 instead of 2-formylbenzoic acid 10 to react with 9*g*, 9*h* or 9*f*, the same procedure as used for the preparation of 11*a–f* led to 16, 17*a* and 17*b*, respectively.

4.4.1. 2-(2-Anilinoethyl)-3-methylene-1-isoindolinone 16. Yellowish oil; yield 94%; ¹H NMR: δ 3.37 (t, *J* = 5.8 Hz, 2H), 3.96 (t, *J* = 6.0 Hz, 2H), 4.06 (br s, 1H, NH), 4.79 (d, *J* = 2.4 Hz, 1H, H^d), 5.12 (d, *J* = 2.7 Hz, 1H, H^c), 6.54 (d, *J* = 7.8 Hz, 2H), 6.60 (t, *J* = 7.3 Hz, 1H), 7.08 (t, *J* = 7.8 Hz, 2H), 7.41 (t, *J* = 7.4 Hz, 1H), 7.49 (t, *J* = 6.9 Hz, 1H), 7.58 (d, *J* = 7.5 Hz, 1H), 7.74 (d, *J* = 7.2 Hz, 1H); ¹³C NMR: δ 38.9, 42.6, 88.8, 112.5, 117.4, 119.9, 123.1, 128.9, 129.3, 129.5, 132.0, 136.3, 141.8, 147.6, 167.9; GC–MS (EI): 264 (M⁺), 159, 119, 106 (base), 77, 51. Anal. calcd for C₁₇H₁₆N₂O: C, 77.25; H, 6.10; N, 10.60. Found: C, 77.08; H, 5.85; N, 10.68%.

4.4.2. (3*S*,9*bS*)-1-Cyclohexyl-3,9*b*-dimethyl-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 17*a*. Colorless oil; yield 88%; $[\alpha]_{\text{D}}^{25} = +2.6$ (*c* 1.50, CHCl₃); ¹H NMR: δ 0.92–1.70 (m, 4H), 1.80–1.31 (m, 2H), 1.42 (d, *J* = 6.3 Hz, 3H), 1.53–1.56 (m, 2H), 1.61 (s, 3H), 1.72–1.82 (m,

1H), 1.83–1.92 (m, 1H), 2.66–2.78 (m, 1H), 3.08 (dd, *J* = 10.5, 7.7 Hz, 1H), 3.61 (dd, *J* = 10.5, 7.8 Hz, 1H), 3.88–4.04 (m, 1H), 7.42–7.58 (m, 3H), 7.76 (d, *J* = 7.2 Hz, 1H); ¹³C NMR: δ 21.7, 23.3, 25.7, 25.8, 26.3, 31.8, 32.4, 50.0, 55.2, 56.2, 86.1, 122.4, 124.3, 128.9, 132.0, 133.2, 148.0, 172.4. Anal. calcd for C₁₈H₂₄N₂O: C, 76.02; H, 8.51; N, 9.85. Found: C, 75.92; H, 8.73; N, 9.59%.

4.4.3. (3*S*,9*bS*)-1-Benzyl-3-isopropyl-9*b*-methyl-1,2,3,9*b*-tetrahydro-5*H*-imidazo[2,1-*a*]isoindol-5-one 17*b*. White needles; yield 89%; mp 157–158°C; $[\alpha]_{\text{D}}^{25} = +25.3$ (*c* 1.51, CHCl₃); ¹H NMR: δ 0.90 (d, *J* = 6.6 Hz, 3H), 1.13 (d, *J* = 6.9 Hz, 3H), 1.66 (s, 3H), 1.74–1.81 (m, 1H), 2.83 (dd, *J* = 9.9, 8.1 Hz, 1H), 3.41 (d, *J* = 9.9 Hz, 1H), 3.44, 3.87 (AB, *J* = 12.9 Hz, 2H), 3.64 (dt, *J* = 7.8, 7.8 Hz, 1H), 7.16–7.26 (m, 5H), 7.36–7.39 (m, 1H), 7.48–7.50 (m, 2H), 7.80 (dd, *J* = 6.1, 3.4 Hz, 1H); ¹³C NMR: δ 18.4, 19.0, 20.9, 35.0, 54.0, 58.9, 60.2, 85.4, 121.7, 124.4, 127.2, 128.3, 128.4, 129.2, 132.1, 132.6, 138.4, 148.1, 173.5. Anal. calcd for C₂₁H₂₄N₂O: C, 78.71; H, 7.55; N, 8.74. Found: C, 78.52; H, 7.66; N, 8.75%.

References

- Geigy, J. R. Neth. Appl. 6,613,264, 1967; *Chem. Abstr.* **1967**, 67, 82204q.
- (a) Graf, W. Swiss 481,123, 1969; *Chem. Abstr.* **1970**, 72, 100709t; (b) Graf, W. Swiss 481,124, 1969; *Chem. Abstr.* **1970**, 72, 100710m.
- Graf, W. Swiss 482,697, 1970; *Chem. Abstr.* **1970**, 73, 25474c.
- (a) Sulkowski, T. S. US 3,663,532, 1972; *Chem. Abstr.* **1972**, 77, 88559n; (b) Sulkowski, T. S. US 3,994,920, 1976; *Chem. Abstr.* **1977**, 86, 106681p.
- Geigy, J. R. Belg. 659,530, 1965; *Chem. Abstr.* **1966**, 64, 6664.
- (a) Sulkowski, T. S.; Wille, M. A.; Mascitti, A.; Diebold, J. L. *J. Org. Chem.* **1967**, 32, 2180–2184; (b) Metlesics, W.; Anton, T.; Sternbach, L. H. *J. Org. Chem.* **1967**, 32, 2185–2187; (c) Houlihan, W. J. US 3,379,733, 1968; *Chem. Abstr.* **1968**, 69, 51995k; (d) Aeberli, P.; Houlihan, W. J. *J. Org. Chem.* **1969**, 34, 1720–1726.
- Cho, C. S.; Jiang, L. H.; Shim, S. C. *Synth. Commun.* **1998**, 28, 849–857.
- Katritzky, A. R.; Xu, Y.-J.; He, H.-Y.; Steel, P. J. *J. Chem. Soc., Perkin Trans. 1* **2001**, 1767–1770.
- Douat, C.; Heitz, A.; Martinez, J.; Fehrentz, J.-A. *Tetrahedron Lett.* **2000**, 41, 37–40.
- Crombie, L.; Hooper, K. C. *J. Chem. Soc.* **1955**, 3010–3016.